| Symbol | QNRX |
|---|---|
| Name | QUOIN PHARMACEUTICALS, LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Medical/Dental Instruments |
| Address | 42127 PLEASANT FOREST COURT, ASHBURN, Virginia, 20148-7349, United States |
| Telephone | +1 703 980-4182 |
| Fax | — |
| — | |
| Website | https://www.quoinpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001671502 |
| Description | Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. Additional info from NASDAQ: |
Director LANGER DENNIS 🟢 acquired 34.5K shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $5.15 Transaction Date: Aug 27, 2026 | Filing ID: 103376
Read moreDirector Culverwell Anthony James 🟢 acquired 31.4K shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $5.15 Transaction Date: Aug 27, 2026 | Filing ID: 103374
Read more(99% Neutral) QUOIN PHARMACEUTICALS, LTD. (QNRX) Provides Update on agents for gross proceeds
Read moreQuoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Read moreQuoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
Read more(99% Neutral) QUOIN PHARMACEUTICALS, LTD. (QNRX) Announces New Board Appointment
Read more(30% Negative) QUOIN PHARMACEUTICALS, LTD. (QNRX) Reports Q3 2026 Financial Results
Read moreQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Read moreQuoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
Read moreNew Form ARS - Quoin Pharmaceuticals, Ltd. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0001104659-26-084081 <b>Size:</b> 17 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07538583 | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Phase2 | Netherton Syndrome | Recruiting | 2026-03-19 | 2027-03-31 | ClinicalTrials.gov |
| NCT06953466 | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Phase2 | Netherton Syndrome | Recruiting | 2025-07-01 | 2026-07-30 | ClinicalTrials.gov |
| NCT05789056 | Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Nethert… | Phase2 | Netherton Syndrome | Recruiting | 2023-03-14 | 2025-12-30 | ClinicalTrials.gov |
| NCT05521438 | Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton S… | Phase2 | Netherton Syndrome | Active_Not_Recruiting | 2022-06-23 | 2026-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| QRX003, 4% Lotion | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT05789056 |
| QRX003, 4% Lotion | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT06953466 |
| QRX003-4% Lotion BID | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| Vehicle | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| QRX003-4% Lotion QAM | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| QRX003-2% Lotion | Other | Phase PHASE2 | Netherton Syndrome | ACTIVE_NOT_RECRUITING | NCT05521438 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |
| QRX003 | Other | Phase PHASE2 | Netherton Syndrome | RECRUITING | NCT07538583 |